Is transesophageal echocardiography necessary before electrical cardioversion in patients treated with non-vitamin K antagonist oral anticoagulants? Current evidence and practical approach by Gorczyca, Iwona et al.
  
ONLINE FIRST
This is a provisional PDF only. Copyedited and fully formatted version will be made available soon.
ISSN: 1897-5593
e-ISSN: 1898-018X
Is transesophageal echocardiography necessary before
electrical cardioversion in patients treated with non-vitamin K
antagonist oral anticoagulants? Current evidence and practical
approach
Authors:  Iwona Gorczyca, Beata Uziębło-Życzkowska, Paweł Krzesiński,
Agnieszka Major, Agnieszka Kapłon-Cieślicka
DOI: 10.5603/CJ.a2021.0129




This article has been peer reviewed and published immediately upon acceptance.
It is an open access article, which means that it can be downloaded, printed, and distributed freely,
provided the work is properly cited.
Articles in "Cardiology Journal" are listed in PubMed. 
Powered by TCPDF (www.tcpdf.org)
Is transesophageal echocardiography necessary before electrical cardioversion in 
patients treated with non-vitamin K antagonist oral anticoagulants? Current evidence 
and practical approach
Iwona Gorczyca et al., Transesophageal echocardiography before electrical cardioversion 
Iwona Gorczyca1, 2, Beata Uziębło-Życzkowska3, Paweł Krzesiński3, Agnieszka Major1, 2, 
Agnieszka Kapłon-Cieślicka4
1Collegium Medicum, The Jan Kochanowski University, Kielce, Poland 
21st Clinic of Cardiology and Electrotherapy, Swietokrzyskie Cardiology Center, Kielce, 
Poland
3Department of Cardiology and Internal Diseases, Military Institute of Medicine, Warsaw, 
Poland
41st Chair and Department of Cardiology, Medical University of Warsaw, Poland
Address for correspondence: Iwona Gorczyca, MD, PhD, 1st Clinic of Cardiology and 
Electrotherapy, Swietokrzyskie Cardiology Center, ul. Grunwaldzka 45, 25-736 Kielce, 
Poland, tel: +48 604 407 956, fax: +48 41 367 13 96, e-mail: iwona.gorczyca@interia.pl
Abstract
According to current guidelines, non-vitamin K antagonist oral anticoagulants (NOACs) 
should be used at least 3 weeks before planned electrical cardioversion. In accordance with 
international atrial fibrillation (AF) guidelines, transesophageal echocardiography (TEE) is a 
pre-procedural examination recommended as an alternative to adequate oral anticoagulation. 
The strategy related to qualifying patients treated with NOACs for pre-procedural TEE differs
in individual centers. Therefore, it is necessary to create an algorithm that will standardize 
estimation of left atrial appendage thrombus (LAAT) prevalence risk and thereby qualify 
NOAC-treated patients to TEE in the most effective way. We assessed the available studies on
LAAT predictors. Risk factors for LAAT formation are not necessarily the same as the risk 
factors for thromboembolic events in patients with AF. The main risk factor for LAAT are as 
follows: previous intracardiac thrombus, irregular use of NOAC, inappropriate dose reduction
of NOAC, previous stroke, CHA2DS2-VASc score ≥ 3 points, glomerular filtration rate < 60 
mL/min/1.73 m2, reduced left ventricular ejection fraction, or left atrial enlargement. Based on
available evidence, we proposed algorithm guarantees more systematic approach to 
performing TEE in patients undergoing electrical cardioversion. 
Key words: electrical cardioversion, non-vitamin K antagonist oral anticoagulant, 
transesophageal echocardiography
INTRODUCTION
Electrical cardioversion (ECV) is a procedure commonly used in AF patients for 
whom a strategy of restoring sinus rhythm was adopted. The EAST (Early treatment of Atrial 
fibrillation for Stroke prevention Trial) study found that early rhythm-control therapy was 
associated with lower risk of cardiovascular outcomes than usual care among patients with 
early atrial fibrillation (AF) and cardiovascular diseases [1]. ECV is a safe practice provided a
patient is appropriately prepared and procedures minimizing risk of thromboembolic 
complications are introduced. In patients with AF undergoing ECV, secondary analyses from 
the landmark non-vitamin K antagonist oral anticoagulant (NOAC) trials, as well as 
prospective randomized trials, showed that NOACs are of similar efficacy and safety to 
warfarin [2–6].
THROMBOEMBOLIC RISK IN THE PERI-CARDIOVERSION PERIOD 
Occurrence mechanisms of thromboembolic complications in patients after ECV can 
be different. Thromboemboli after ECV are thought to be caused by embolization of already 
existing thrombi present in the left atrial appendage (LAA) at the time of ECV. In the first 
weeks after ECV atrial function is depressed, impairing the left atrium’s ability to empty 
sufficiently.
This impairment could lead to formation of thrombi even if their presence had not 
been diagnosed before ECV [7, 8]. Therefore, performing transesophageal echocardiography 
(TEE) before ECV and excluding thrombus in the left atrium does not guarantee that after 
ECV emboli will not be formed. In the analysis of the data from 32 studies and a total number
of 4,621 patients, 92 patients had a thromboembolic event after ECV. Thromboembolic 
complications appeared from 1 to 18 days after ECV. It was shown that the vast majority of 
events occurred within 72 hours of ECV, 82% of thromboembolic complications appeared in 
3 days, 96% in 1 week, and 98% within 10 days of ECV [9].
The results of studies to date confirm that the proportion of thromboembolic 
complications after ECV in patients effectively treated with anticoagulant drugs is not high. 
Among 1613 AF patients treated with NOACs or vitamin K antagonists (VKAs) and 
undergoing ECV there were no differences in the incidence of stroke or transient ischemic 
attack (TIA) within the first year after ECV [10]. The results of the study by Frederiksen et al.
[11] involving a group of 2150 patients undergoing ECV were consistent with the results of 
the previous study. Thromboembolic complications were not observed in any of the patients 
during the 30-day follow-up period of this study, which included 668 patients treated with 
NOACs before ECV [12]. Also, Barysiene et al. [13] did not acknowledge thromboembolic 
events in the 30-day follow-up period for a group of 432 patients receiving pertinent 
anticoagulant therapy prior to ECV. A meta-analysis of four randomized controlled trials 
comparing NOAC therapy with VKA, including 4517 cardioversions, showed that the 
thromboembolic complication rate was 0.4% in patients treated with NOACs and 0.6% in 
patients treated with VKAs [14]. Another meta-analysis involving seven trials and 7588 
patients undergoing ECV showed that NOACs, as compared to warfarin, resulted in similar 
risks of ischemic stroke (0.19% vs. 0.53%) after ECV [15]. 
PREVALENCE OF THROMBI IN THE LAA AND THEIR RISK FACTORS
In AF patients, thromboembolic material localized in the left atrium is most frequently 
observed in the LAA. The prevalence of LAA thrombus (LAAT) in patients undergoing 
anticoagulant therapy was assessed in numerous studies (Table 1).
Risk factors for LAAT formation are not clearly defined and are not necessarily the 
same as the risk factors for thromboembolic events in patients with AF. The main 
pathophysiological theory of atrial thrombogenesis in AF relates to endocardial remodeling 
[31]. Oxidative stress and inflammation in fibrillating atrial tissue are the main factors 
influencing up-regulation of thrombogenic proteins at the endocardial surface. 
The precursor of LAAT is a spontaneous echo contrast (SEC) described as discrete 
reflections that are visible in blood inside cardiac cavities, chambers, or vessels. Smoke-like 
SEC is defined as swirling, amorphous, light gray haze [32]. Its acoustic density and 
configuration alter within several cardiac cycles. It is possible to notice it in veins, great 
vessels, and in left and right heart chambers. Smoke-like SEC shows a strong connection to 
thromboembolic events and stroke [34] and its probable cause is blood stasis [33]. Non-smoke
SEC looks like a ‘snowstorm’ or like discrete dispersed reflections in normal conditions. 
Respiratory maneuvers can enhance such SEC in the left atrium. Its intensity can be mild to 
moderate and conditioned by transient stasis, especially in the pulmonary circulation. LAA 
sludge signalizes a dynamic, viscid, layered echo dense finding without a discrete mass. Its 
density seems higher than that of SEC and lower than that of a thrombus. Thus, it is believed 
to be a stage between SEC and thrombus formation [35].
Concomitant diseases such as arterial hypertension, diabetes mellitus, heart failure, 
and advanced age appear to have an important impact on endocardial remodeling. 
In most studies LAAT prevalence was higher in patients with the higher CHA2DS2-
VASC score. However, it was proven that LAAT appeared in patients without risk factors 
included in the CHA2DS2-VASC score. Therefore, it is necessary to search for LAAT risk 
factors that are different from the classic thromboembolic ones. A study of 1,033 patients 
revealed renal function and AF type as strong and independent predictors of LAAT. This same
study suggested the CHA2DS2-VASC score be extended and that it might be considered an 
effective tool for LAAT prevalence assessment (Table 2) [29]. Further studies showed that the 
CHA2DS2-VASc-RAF score was a better LAAT prevalence predictor than the CHA2DS2-
VASc score in patients treated with NOACs [36]. Therefore, using the CHA2DS2-VASc-RAF 
score or taking into account all additional factors included in it (renal function, AF type) in the
assessment of LAAT prevalence risk may be helpful in making decisions on TEE 
performance. Huang et al. [19] proposed a new scoring system established as the LAAT/SEC 
predictive score, in which the following parameters were included: non-paroxysmal AF, left 
ventricular ejection fraction < 55%, and left atrial enlargement (Table 2). 
TEE-GUIDED CARDIOVERSION 
According to current guidelines issued by the European Society of Cardiology (ESC), 
early cardioversion can be done without TEE in patients with AF duration < 48 hours. 
Suitable oral anticoagulation is recommended for at least 3 weeks before ECV in patients with
AF > 48 hours or of unknown duration [37]. This recommendation is the same for all patients,
independent of stroke risk, according to the CHA2DS2-VASC score. This 3-week period of 
adequate anticoagulant treatment is necessary, based on the time presumably needed for 
endothelialization or resolution of possible LAAT. To shorten this time, experts recommended
TEE to exclude LAAT as an alternative to a 3-week anticoagulation period when early 
cardioversion is planned [37]. Recommendations from the ESC and the American Society of 
Cardiology for the aforementioned issue are consistent [37, 38] with previous ESC guidelines 
[39]. 
TEE BEFORE ECV IN CLINICAL PRACTICE 
In clinical practice, procedures related to performing TEE in patients using NOACs 
and undergoing planned ECV are different at individual centers. In the case of patients treated
with VKAs, the international normalized ratio value from three weeks before ECV proves that
anticoagulant treatment is adequate. Thus far, none of the coagulation parameters were 
considered to be indicators confirming regular use of NOACs. Therefore, in the absence of 
laboratory confirmation of regular NOAC use, patients undergo TOE prior to ECV.
Results of the European Heart Rhythm Association survey from 2019 included 54 
centers and found that most would also perform TEE in patients with AF lasting ≥ 48 hours in
case of no or incomplete information (80% and 78%, respectively) about adequate 
anticoagulation. Only 12% of the centers would routinely perform TEE before any LA 
procedure, regardless of the thromboembolic risk [40]. The results of the same survey from 
2013 are not consistent with the above-mentioned practice. In 56.5% of centers where patients
were not on adequate anticoagulation therapy, TEE was performed. An additional 4.6% of the 
centers recommended TEE routinely for all patients [41]. In the study including 668 AF 
patients treated with NOACs before ECV, TEE was performed in 54% of patients [12]. Data 
from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II showed 
that 25% of patients had pre-cardioversion TEE [10].
WHEN TEE SHOULD BE MADE BEFORE ECV: PRACTICAL DECISION 
ALGORITHM
Data referring to the frequency of TEE procedures in patients with AF treated with 
NOACs are not consistent and show diverse strategies among individual centers performing 
ECV. 
Current ESC guidelines lack the possibility of standardizing how NOAC action is 
monitored, indicating the need to search for new patterns that can be used to determine which 
AF patients would be served with TEE prior to ECV. The data indicates that performing pre-
cardioversion TEE in all patients treated with NOACs is not optimal, nor is exempting them 
all from TEE before ECV.
There is a great deal of evidence indicating that, according to the CHA2DS2-VASc 
score, high risk of thromboembolic complications in patients treated with NOACs is a 
predictor of LAAT. In the study of Gorczyca et al. [26] the LAAT predicting factor was a 
CHA2DS2-VASc score ≥ 2 points, and in the study of Gunawardene et al. [17] CHA2DS2-
VASc score ≥ 4 points was predictive. However, using this score alone for patient assessment 
may not be the most thorough approach possible, given that other conditions also present the 
same results. In some situations, it is necessary to diagnose LAAT risk based on a patient`s 
detailed clinical characteristics and not the result of a particular score. 
For the systematic approach to performing TEE before ECV we propose a decision-
making algorithm, presented in Figure 1. We have merged widely accessible clinical features, 
identified in the above-discussed studies as the risk factors of LAAT, in a simple screening 
path. In patients with AF using NOACs before planned ECV, pre-procedural TEE should be 
performed in those who had LAAT in the past, regardless of treatment strategy, and also in 
those with any suspicion of unsystematic NOAC use. In the remaining patients, the necessity 
for TEE should be decided upon after considering individual thromboembolic risk. According 
to the presented algorithm, TEE should be performed in patients with any strong LAAT risk 
factor such as: previous intracardiac thrombus, irregular use of NOAC, inappropriate dose 
reduction of NOAC, previous stroke/TIA/systemic embolism, CHA2DS2-VASc score ≥ 3 
points, glomerular filtration rate < 60 mL/min/1.73 m2, reduced left ventricular ejection 
fraction, or moderate or severe left atrial enlargement (Central illustration).
TEE: LIMITATIONS OF THE METHODS
Transesophageal echocardiography is a minimally invasive procedure that is usually 
safer when conducted by an experienced physician. However, it is time consuming, carries 
patient discomfort, is not readily available in all centers, and sometimes it is associated with 
potential life-threatening complications. Although TEE is regarded as the gold standard to 
exclude a thrombus in the LAA before scheduled ablation or AF cardioversion, the accuracy 
of this technique is far from 100%. In patients who present contraindication to TEE or do not 
agree to have this examination, computed tomography or magnetic resonance imaging can be 
considered reasonable alternatives to TEE in the identification of LAAT. Multidetector 
computed tomography provides three-dimensional volumetric data of the entire heart, 
including the LAA. It is of high spatial and temporal resolution, which allows the 
identification of LAAT and spontaneous contrast formation similar to the SEC observed by 
TEE. Cardiac magnetic resonance with its high temporal resolution shows the LAA size and 
function and can detect LAAT in AF patients. A recently conducted systematic review and 
meta-analysis of 4 cardiac magnetic resonance and 22 multidetector computed tomography 
studies juxtaposed TEE with the diagnostic performance of listed methods for LAAT 
identification. Sensitivity and specificity of multidetector computed tomography were, 
respectively, 0.99 and 0.94 compared to TEE, with notably increased specificity of the 
delayed imaging protocols. Cardiac magnetic resonance, in comparison to TEE, demonstrated
sensitivity and specificity of 0.80 and 0.98, respectively [42]. It seems that in clinical practice 
the main limitation of TEE is lack of common TEE accessibility in all centers performing 
ECV. 
SUMMARY
Due to the high risk of LAAT and lack of standardized laboratory tests confirming the 
efficacy of NOAC, it seems necessary to define guidelines for performing TEE prior to ECV. 
It appears that risk factors of thromboembolic complications and LAAT are not the same. In 
patients with low thromboembolic risk, it is especially important to consider additional factors
that increase the risk of LAAT prevalence. The proposed algorithm guarantees a more 
systematic approach to performing TEE in patients undergoing ECV. 
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Central illustration. The algorithm proposed for assessing indications for transesophageal 
echocardiography before planned electrical cardioversion in patients treated with non-vitamin 
K oral anticoagulants; AF — atrial fibrillation; GFR – glomerular filtration rate; LA — left 
atrial; LAVI — left atrial volume index; LVEF — left ventricular ejection fraction; NOAC — 






Previous intracardiac thrombus 
AF patients
treated with NOAC for 3 weeks
No 
Irregular use of NOAC
No 














LA enlargement — LAVI > 41 mL/m2
Yes 
No No TEE
Table 1. The prevalence and risk factors of a left atrial appendage thrombus in the selected 
studies. 




















732 57 (11) 77 1.6 CHADS2 ≥ 2
LA diameter ≥ 45 mm
McCready [19], 
2010





329 62 (10) 65 2.1 CHA2DS2-VASC ≥ 4
CHADS2 ≥ 3
Diabetes mellitus
Wu [21], 2018 608 65 (58–
71)
72 2.8 Congestive heart failure 
Moderate/severe LA enlargement 
Yamashita [22], 
2010














74 3.6 Heart failure
Persistent AF






GFR < 60 mL/min/1.73 m2
Gorczyca [26], 
2020
1148 62.1 61.9 4.4 CHA2DS2‐VASc ≥ 2 
Non‐paroxysmal AF 
GFR < 60 mL/min/1.73 m2
Harada [27], 
2018
407 63 (12) 71 4.4 Persistent AF 














66 5.71 CHA2DS2-VASC score
GFR < 56 mL/min/1.73 m2
Non-paroxysmal AF
Merino [30], 1183 – – 8.2 Heart failure
2019 Age
AF — atrial fibrillation; GFR — glomerular filtration rate; LA — left atrial; LAAT — left 
atrial appendage thrombus; LV — left ventricle; LVEF — left ventricular ejection fraction; 
TIA — transient ischemic attack
Table 2. The proposal of a left atrial appendage thrombus risk stratification model: the 
CHA2DS2-VASc-RAF score and the left atrial appendage thrombus/spontaneous echo contrast
score.
AF — atrial fibrillation; GFR — glomerular filtration rate; LA — left atrial; LVEF — left 







Congestive heart failure 1 –
Hypertension 1 –
Diabetes mellitus 1 –
Vascular disease 1 –
Age 65–74 years 1 –
Stroke/TIA/systemic embolism 2 –
Age ≥ 75 years 2 –
Female sex 1 –
GFR < 56 mL/min/1.73 m2 2 –
Persistent AF 4 1
Permanent AF 10 1
LVEF < 55% – 2
LA enlargement (> 38 mm for 
women, > 40 mm for men)
– 3
Risk categories
Low 0–4 points in men
1–5 points in women
0–1 point
Intermediate – 2–3 points
High ≥ 5 points in men
≥ 6 points in women
4–6 points
